Acute promyelocytic leukemia: from highly fatal to highly curable.
about
A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discoveredInduction of metallothionein I by arsenic via metal-activated transcription factor 1. Critical role of c-terminal cysteine residues in arsenic sensingCritical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemiaEffects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (APL))Idarubicin compared to other anthracyclines for treatment of newly diagnosed acute myeloid leukaemiaArsenic trioxide for the treatment of acute promyelocytic leukaemiaArsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodiesFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaPLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomasDistinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cellsHistone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsRedox-directed cancer therapeutics: molecular mechanisms and opportunitiesBiomarkers of Nutrition for Development (BOND)-Vitamin A ReviewSingle-Cell Sequencing Technology in Oncology: Applications for Clinical Therapies and ResearchThe blind men and the AML elephant: can we feel the progress?Bridging academic science and clinical research in the search for novel targeted anti-cancer agentsAcute promyelocytic leukemia: where did we start, where are we now, and the futureThe cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodiesPerspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogsHow animal models of leukaemias have already benefited patientsPathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndromeThyroid tumor-initiating cells: increasing evidence and opportunities for anticancer therapy (review)Progress in acute myeloid leukemiaTreatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patientsMechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.Arsenic toxicity to Saccharomyces cerevisiae is a consequence of inhibition of the TORC1 kinase combined with a chronic stress responseVitamin A, cancer treatment and prevention: the new role of cellular retinol binding proteinsRegulation of Cellular Identity in CancerRaf kinases in cancer-roles and therapeutic opportunitiesMechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemiaA systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemiaReactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosisArsenic exposure and the induction of human cancersArsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET proteinArsenic trioxide induces apoptosis in human platelets via C-Jun NH2-terminal kinase activationMatrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxideRetinoids in the treatment of glioma: a new perspective.Arsenic trioxide alters the differentiation of mouse embryonic stem cell into cardiomyocytes.
P2860
Q23671266-85389F13-9E68-4B69-BEBD-ABD637010C39Q23923855-CA33C8E1-5839-4602-A025-5F99CCE3B038Q23923913-2A587D51-2C42-4FF9-AA82-0CA5D41E3ED8Q24187297-2B9BCFA3-2459-466B-A049-1027A5C67E8AQ24188096-81107B8C-C49D-43C1-8ED5-1ADC001F852AQ24200407-E3A93545-FEA7-4BCB-82D5-4352D5FB497AQ24239914-F14D1C80-94D6-415D-953F-EE112B1A119FQ24302645-1DC354E4-79AD-4C9B-AB69-77BD0656BC0CQ24605527-279CED80-CE9B-4BAC-8468-C0FA902EADFCQ24615768-2C6EFF93-B51E-4923-861D-6DF83BCDC388Q24632284-B6B5A3FB-15E4-416C-856C-ED6E066FE9A4Q24633763-6E2E300F-EE16-481D-BD0A-C6566E6FF1BBQ24645584-BA17E7CB-F86F-4338-A6FC-777F10905014Q26741961-49595F14-10E1-4BEB-9AB9-D51D008A3464Q26744582-B4FECF6D-DEE0-48AC-8743-C5151F13BBF3Q26749614-FBCD3D1E-93AC-4911-8E7F-E3E8E917BFDAQ26771396-FF58A408-0A6F-4B03-980E-878903EB3FCCQ26830385-259AF2C6-7EE0-45D6-9EB5-7F83EB2A0A85Q26853348-D9B96C16-9C89-428C-A8B2-203BADEEE331Q26991440-E1943CB2-CC8F-4199-81D9-7F8B4D5DEE59Q26997702-11B2220B-6043-464E-9BC2-789320A0FFE0Q27012691-F3B70CA7-4F8A-4A63-AC12-BF687ED32C11Q27015644-297B40B7-CB5D-4207-B110-3CCDD05E5530Q27024006-CC8838D8-D63E-4CEA-A31C-5222A1D4BDF7Q27851636-E3E0404B-3C2C-4B53-8D50-FFCA62BB419BQ27852289-B6A43F4A-7BC0-4DD1-AE25-A55BDE5FE0E4Q27930076-4D425CD5-2A98-408F-83B2-CC842940674AQ28081177-AABD5E2A-55AA-423A-8C3B-3DA184F53B3DQ28086849-BB9C5F63-526E-4EDF-90A5-E09FD59E35F0Q28237793-5CB7E338-484B-4F00-B066-5CBA6D63BBE0Q28385690-74C2BCCE-4CE5-4B6A-BE77-588B41D6A0D3Q28387697-487110AA-EDF1-4E88-9C16-75D66DAB6157Q28388476-F1E2185D-4A09-43E6-81D5-86F34B6B158AQ28394700-04CDB2C9-F923-49F2-A27B-AD97DEFE4390Q28481142-E1675C9B-6B76-47A2-9CBB-1CBF3AC12CB5Q28538642-B7B6423D-7808-4537-AF3F-69C28E11995EQ28539034-FFE2C3F3-EC98-420C-9EF8-1F65D0298E0EQ28539921-7D5F64EB-852D-4926-B076-A1EC62312E58Q30464615-8A3BE41B-9DEF-417C-B10A-1E8716B417C5Q30667180-420B274B-C278-41B1-A97A-E3F23B26498B
P2860
Acute promyelocytic leukemia: from highly fatal to highly curable.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Acute promyelocytic leukemia: from highly fatal to highly curable.
@ast
Acute promyelocytic leukemia: from highly fatal to highly curable.
@en
Acute promyelocytic leukemia: from highly fatal to highly curable.
@nl
type
label
Acute promyelocytic leukemia: from highly fatal to highly curable.
@ast
Acute promyelocytic leukemia: from highly fatal to highly curable.
@en
Acute promyelocytic leukemia: from highly fatal to highly curable.
@nl
prefLabel
Acute promyelocytic leukemia: from highly fatal to highly curable.
@ast
Acute promyelocytic leukemia: from highly fatal to highly curable.
@en
Acute promyelocytic leukemia: from highly fatal to highly curable.
@nl
P1433
P1476
Acute promyelocytic leukemia: from highly fatal to highly curable.
@en
P2093
Zhen-Yi Wang
P304
P356
10.1182/BLOOD-2007-07-102798
P407
P577
2008-03-01T00:00:00Z